Zürcher Nachrichten - First person vaccinated during trial of new Ebola jab

EUR -
AED 4.179616
AFN 75.678542
ALL 93.750507
AMD 416.391061
AOA 1043.62306
ARS 1701.742833
AUD 1.62823
AWG 2.048552
AZN 1.939126
BAM 1.95482
BBD 2.291551
BDT 140.33961
BHD 0.429077
BIF 3398.920554
BMD 1.138084
BND 1.468638
BOB 12.634496
BRL 5.77703
BSD 1.137729
BTN 109.806478
BWP 15.715703
BYN 3.263378
BYR 22306.449845
BZD 2.288212
CAD 1.602206
CDF 2569.793986
CHF 0.930242
CLF 0.027302
CLP 1074.590078
CNY 7.705114
CNH 7.707203
COP 3656.550648
CRC 517.728952
CUC 1.138084
CUP 30.159231
CVE 110.212626
CZK 24.135916
DJF 202.593046
DKK 7.475625
DOP 66.255604
DZD 151.799566
EGP 58.440507
ERN 17.071263
ETB 183.635495
FJD 2.56217
FKP 0.855066
GBP 0.853328
GEL 2.987506
GGP 0.855066
GHS 13.231189
GIP 0.855066
GMD 84.21797
GNF 9982.256374
GTQ 8.679418
GYD 238.024341
HKD 8.925175
HNL 30.473314
HRK 7.535027
HTG 148.752777
HUF 360.796561
IDR 20399.419096
ILS 3.467003
IMP 0.855066
INR 109.67484
IQD 1490.432806
IRR 1565178.714879
ISK 143.01197
JEP 0.855066
JMD 180.459488
JOD 0.806855
JPY 186.34592
KES 147.313836
KGS 99.525882
KHR 4600.571239
KMF 492.790428
KRW 1662.194735
KWD 0.352874
KYD 0.948099
KZT 540.951547
LAK 25761.626127
LBP 101881.909096
LKR 382.338232
LRD 205.921289
LSL 19.216155
LTL 3.360467
LVL 0.688415
LYD 7.280476
MAD 10.654656
MDL 20.108384
MGA 5041.38282
MKD 61.539404
MMK 2390.228125
MNT 4091.090922
MOP 9.189848
MRU 45.408626
MUR 53.968211
MVR 17.58333
MWK 1972.758529
MXN 19.873851
MYR 4.656363
MZN 72.695153
NAD 19.216408
NGN 1555.066937
NIO 41.869
NOK 10.896906
NPR 175.689793
NZD 1.963856
OMR 0.437575
PAB 1.137709
PEN 3.871858
PGK 5.089581
PHP 70.280141
PKR 316.032789
PLN 4.314471
PYG 6878.580159
QAR 4.136198
RON 5.23211
RSD 117.434388
RUB 88.366048
RWF 1676.414977
SAR 4.281093
SBD 9.196978
SCR 15.207023
SDG 683.418008
SEK 11.04715
SGD 1.468601
SLE 27.626995
SOS 650.162475
SRD 43.011047
STD 23556.044655
STN 24.487395
SVC 9.955269
SZL 19.213857
THB 38.310187
TJS 10.495259
TMT 3.983295
TND 3.372309
TRY 53.883053
TTD 7.730021
TWD 36.836941
TZS 3007.383804
UAH 50.98917
UGX 4288.84886
USD 1.138084
UYU 45.689091
UZS 13768.912508
VES 843.606486
VND 29962.342095
VUV 134.847547
WST 3.124845
XAF 655.610886
XAG 0.019474
XAU 0.00028
XCD 3.075729
XCG 2.050472
XDR 0.815921
XOF 655.645433
XPF 119.331742
YER 270.960517
ZAR 19.136089
ZMK 10244.137451
ZMW 21.076059
ZWL 366.46264
  • CMSD

    0.0250

    22.025

    +0.11%

  • RIO

    0.5300

    92.04

    +0.58%

  • BCC

    1.3750

    77.835

    +1.77%

  • CMSC

    -0.0400

    21.75

    -0.18%

  • JRI

    0.0400

    12.94

    +0.31%

  • BCE

    0.1050

    21.315

    +0.49%

  • GSK

    0.4600

    51.2

    +0.9%

  • RBGPF

    -0.7300

    66

    -1.11%

  • BTI

    1.0500

    60.89

    +1.72%

  • RYCEF

    -0.1600

    18.09

    -0.88%

  • BP

    -0.2200

    43.71

    -0.5%

  • RELX

    1.3750

    34.235

    +4.02%

  • AZN

    0.1050

    168.375

    +0.06%

  • VOD

    -0.0250

    15.225

    -0.16%

  • NGG

    0.1850

    82.555

    +0.22%

First person vaccinated during trial of new Ebola jab
First person vaccinated during trial of new Ebola jab / Photo: BENEDICTION MURHABAZI - AFP/File

First person vaccinated during trial of new Ebola jab

A volunteer was injected on Friday with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola driving a deadly outbreak in the Democratic Republic of Congo, Oxford University said.

Text size:

More than 1,000 people have been killed in the DRC and Uganda since the outbreak emerged in May, according to the World Health Organization.

Researchers and health organisations have since been racing to get a vaccine or treatment for the relatively rare strain to the clinical trial stage where it is tested on humans.

Earlier this month, a team at Oxford University in the UK announced it was launching the first trial for its ChAdOx1 BDBV vaccine, which uses the same technology as AstraZeneca's Covid-19 vaccine.

The first dose was administered to a 37-year-old volunteer named Ed Hunt in Oxford on Friday, a university spokesman told AFP.

"We've taken this vaccine candidate from concept to clinic in just eight weeks," David Pulido-Gomez of Oxford's Pandemic Sciences Institute said in a statement.

"Reaching this milestone in such a short timeframe reflects an extraordinary collaborative effort," he added.

The trial received funding from the Coalition for Epidemic Preparedness Innovations (CEPI), while the Serum Institute of India has already manufactured a stockpile of 620,000 doses.

The phase 1 trial plans to assess the safety and effectiveness of the vaccine in 50 health adults in the coming weeks. The researchers are currently recruiting more volunteers.

Given regulatory approval, the team is preparing for more clinical studies of the vaccine with partners in Uganda, Oxford said.

Several other Bundibugyo vaccine candidates are also being urgently developed towards the trial stage, while two potential treatments are being worked on.

The Ebola outbreak is the 17th in the DRC's history, but just the third caused by the Bundibugyo strain, for which there are no approved vaccines or treatments.

WHO chief Tedros Adhanom Ghebreyesus warned last week that the outbreak had over the past month "expanded faster than any previous outbreak" of Ebola.

The outbreak has remained concentrated in the vast country's mineral-rich and conflict-plagued northeastern province.

Cases of Ebola, which spreads through close contact and infected bodily fluids, have also been found in four other DRC provinces.

T.L.Marti--NZN